Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial
The DOI matches its Crossref record, with a small difference in title or year; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: New-onset diabetes after transplantation (NODAT) is a serious complication after kidney transplantation affecting graft and patient survival. Currently, no guidelines exist for the management of renal transplant patients with impaired glucose tolerance (IGT), a risk factor for the development of NODAT and an independent predictor of death. METHODS: In a population of 48 stable renal transplant recipients at least 6 months from time of transplantation with newly diagnosed IGT, we tested the dipeptidylpeptidase-4 inhibitor vildagliptin, the thiazolidinedione pioglitazone, or placebo for 3 months in addition to lifestyle counseling. Outcome measures were difference in change in oral glucose tolerance test between the groups and between baseline and end of study as well as change in HbA1c, serum lipids, and renal and hepatic function. RESULTS: In both treatment groups, 2-hr plasma glucose at 3 months was significantly reduced compared with baseline (vildagliptin: -20±24 mg/dL; P=0.002 and pioglitazone: -23±29 mg/dL; P=0.004), and pioglitazone also significantly improved fasting plasma glucose (-11±14 mg/dL; P=0.003), although the primary outcome (difference in change in 2-hr plasma glucose among the three groups) did not reach statistical significance. Furthermore, HbA1c was decreased in both treatment arms (vildagliptin: -0.1%±0.3%; P=0.046 and pioglitazone: -0.2%±0.3%; P=0.029). In the placebo group, no significant changes in these parameters were observed. Only mild adverse events occurred and at a similar rate in all three groups. CONCLUSIONS: These data demonstrate that both vildagliptin and pioglitazone are of potential benefit in patients with IGT after renal transplantation in addition to lifestyle modification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An increasing body of new literature points to the association of immune checkpoint inhibitors with new-onset hyperglycemia and DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1603]
In the citing paper
“At this time, most of the literature is in the form of case reports demonstrating hyperglycemia, new-onset diabetes, and DKA, either with or without autoimmune markers of T1D.1579,1600–1605”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1603]
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“The thiazolidinedione rosiglitazone was associated with an increased cardiovascular risk and therefore withdrawn from the market (34).”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone even led to a significant reduction in liver enzymes, as it has already been observed by others (32).”
BackgroundStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Bantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396 · cited 1×
“In nontransplanted individuals, approximately 25% of patients with prediabetes develop overt diabetes within 3 to 5 years and approximately 50% remain in their abnormal glycemic state (5).”
BackgroundDiabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Long-term efficacy and safety cannot be judged from this study and it is still under debate whether incretin-based therapies confer a risk for pancreatitis, pancreatic cancer, and thyroid cancer (33).”
BackgroundPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 2×
“Pioglitazone has already been shown to prevent the development of diabetes in patients with IGT in a study with more than 600 patients (72% risk reduction for conversion of prediabetes to overt diabetes), whereas vildagliptin holds promise in protecting A-cell function during the transition from prediabetes to type 2…”
Backgroundβ-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Cited by
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“Werzowa et al (48) reported a randomized controlled trial comparing safety and efficacy of vildagliptin (dipeptidylpeptidase-4 inhibitor) with pioglitazone (thiazolidinedione) or placebo in kidney allograft recipients with impaired glucose tolerance.”
BackgroundSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Metformin and other antidiabetic agents in renal failure patients
Lalau, J., Arnouts, P., Sharif, A., & Broe, M. E. D. (2014) · Kidney International · doi:10.1038/ki.2014.19 · Cited by 159
Deacon, C. F., & Holst, J. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824966 · Cited by 122
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
Self-citationInternational consensus on post-transplantation diabetes mellitus
Sharif, A., Chakkera, H. A., de Vries, A. P. J., Eller, K., Guthoff, M., Haller, M. C., Hornum, M., Nordheim, E., Kautzky‐Willer, A., Krebs, M., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad258 · Cited by 146
Self-citationHaidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12518 · Cited by 110
Self-citationScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft536 · Cited by 89
Post-transplantation diabetes—state of the art
Sharif, A., & Cohney, S. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00387-3 · Cited by 99
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 89
Conte, C., & Secchi, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1137-8 · Cited by 81
Lv, C., Zhang, Y., Chen, X., Huang, X., Xue, M., Sun, Q., Wang, T., Liang, J., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12275 · Cited by 69
Complications of Solid Organ Transplantation
Sen, A., Callisen, H. E., Libricz, S. L., & Patel, B. M. (2018) · Critical Care Clinics · doi:10.1016/j.ccc.2018.08.011 · Cited by 81
Post-Transplantation Diabetes Mellitus
Ahmed, S. H., Biddle, K., Augustine, T., & Azmi, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00790-5 · Cited by 77
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
Management of metabolic syndrome and cardiovascular risk after liver transplantation
Fatourou, E. M., & Tsochatzis, E. A. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30181-5 · Cited by 59
New‐onset diabetes after renal transplantation
Tufton, N., Ahmad, S., Rolfe, C., Rajkariar, R., Byrne, C., & Chowdhury, T. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12534 · Cited by 56
Boerner, B. P., Miles, C. D., & Shivaswamy, V. (2014) · International Journal of Endocrinology · doi:10.1155/2014/617638 · Cited by 55
Metabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 65
Liou, J.-H., Liu, Y.-M., & Chen, C.-H. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.087 · Cited by 55
Vanhove, T., Remijsen, Q., Kuypers, D. R. J., & Gillard, P. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.09.001 · Cited by 56
Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update
Rodríguez‐Rodríguez, A. E., Porrini, E., Hornum, M., Donate‐Correa, J., Febles, R. M., Ramchand, S. K., Lima, M. X. M., & Torres, A. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000514288 · Cited by 50
Lo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 41
Langsford, D., & Dwyer, K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1132 · Cited by 44
Non-immunological complications following kidney transplantation
Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 49
Cardiovascular complications after transplantation: Treatment options in solid organ recipients
Gillis, K. A., Patel, R. K., & Jardine, A. G. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.001 · Cited by 39
Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 42
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 36
Kanbay, M., Çöpür, S., Topçu, A. U., Güldan, M., Özbek, L., Gaipov, A., Ferro, C. J., Cozzolino, M. G., Cherney, D. Z. I., & Tuttle, K. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15575 · Cited by 36
Hornum, M., Lindahl, J. P., von Zur‐Mühlen, B., Jenssen, T. G., & Feldt‐Rasmussen, B. (2013) · Transplant International · doi:10.1111/tri.12112 · Cited by 29
Pisano, G., Fracanzani, A. L., Caccamo, L., Donato, M. F., & Fargion, S. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i40.8869 · Cited by 31
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
Anderson, S., Cotiguala, L., Tischer, S. M., Park, J. M., & McMurry, K. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020951955 · Cited by 28
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 26
Early Post-Renal Transplant Hyperglycemia
Iqbal, A., Zhou, K., Kashyap, S. R., & Lansang, M. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab697 · Cited by 32
Lawrence, S. E., Chandran, M. M., Park, J. M., Sweiss, H., Jensen, T. B., Choksi, P. U., & Crowther, B. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14922 · Cited by 23
Bundhun, P. K., Janoo, G., Teeluck, A. R., & Huang, F. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0175-0 · Cited by 22
Risk assessment and management of post-transplant diabetes mellitus
Han, E., Kim, M. S., Kim, Y. S., & Kang, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.011 · Cited by 30
Suarez, O., Pardo, M., Gonzalez, S., Escobar-Serna, D. P., Castañeda-Millán, D. A., Rodríguez, D., Osorio, J. C., & Lozano, E. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.07.011 · Cited by 21
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
Lim, S. W., Jin, J. Z., Jin, L. G., Jin, J., & Li, C. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.759 · Cited by 28
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach
Ducloux, D., & Courivaud, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010116 · Cited by 20
Arashnia, R., Roohi-Gilani, K., Karimi‐Sari, H., Nikjoo, N., & Bahramifar, A. (2015) · Europe PMC (PubMed Central) · doi:10.12860/jnp.2015.10 · Cited by 16
Post‐transplantation diabetes mellitus: evaluation of treatment strategies
Haidinger, M., Antlanger, M., Kopecky, C., Kovarik, J. J., Säemann, M. D., & Werzowa, J. M. (2015) · Clinical Transplantation · doi:10.1111/ctr.12541 · Cited by 17
Self-citationProgress of new-onset diabetes after liver and kidney transplantation
Zhang, Z., Sun, J., Meng, G., & Yuan, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1091843 · Cited by 18
The Diagnosis of Posttransplantation Diabetes Mellitus: Meeting the Challenges
Werzowa, J. M., Hecking, M., Haidinger, M., Döller, D., Sharif, A., Tura, A., & Säemann, M. D. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0601-x · Cited by 14
Self-citationLo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Antidiabetic therapy in post kidney transplantation diabetes mellitus
Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 14
Self-citationSantos, R. B. D., Hagopian, J. C., Chen, L., Ramakrishnan, M., Wijeweera, H., Klein, C. L., & Brennan, D. C. (2022) · Transplantation · doi:10.1097/tp.0000000000004373 · Cited by 13
Thiruvengadam, S., Hutchison, B., Lim, W., Bennett, K., Daniels, G., Cusack, N., Jacques, A., Cawley, B., Thiruvengadam, S., & Chakera, A. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.020 · Cited by 11
Klangjareonchai, T., Eguchi, N., Tantisattamo, E., Ferrey, A., Reddy, U. G., Dafoe, D. C., & Ichii, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030413 · Cited by 12
Renal posttransplantation diabetes mellitus: An overview
Pimentel, A. L., Bauer, A. C., & Camargo, J. L. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.09.010 · Cited by 13
DPP-4 Inhibitor Therapy in Patients after Pancreatic Transplant
Ergin, A. B., Poggio, E. D., Krishnamurthi, V., Jaber, T., & Hatipoğlu, B. (2015) · Endocrine Practice · doi:10.4158/ep14243.or · Cited by 9
Phillips, J., Chen, J. H. C., Ooi, E. M. M., Prunster, J., & Lim, W. H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.731574 · Cited by 11
New onset of diabetes after transplant
Egan, L., & Sheejo, S. (2019) · Journal of Kidney Care · doi:10.12968/jokc.2019.4.4.180 · Cited by 7
Gaiffe, É., Crépin, T., Bamoulid, J., Courivaud, C., Büchler, M., Cassuto, É., Albano, L., Chemouny, J., Choukroun, G. J., Hazzan, M., et al. (2019) · Trials · doi:10.1186/s13063-019-3392-6 · Cited by 8
Almdal, K., Hornum, M., & Almdal, T. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221107121900 · Cited by 8
Raven, L. M., Muir, C. A., Macdonald, P. S., Hayward, C., Jabbour, A., & Greenfield, J. R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02018-3 · Cited by 6
Xue, M., Lv, C., Chen, X., Huang, X., Sun, Q., Wang, T., Liang, J., Zhang, Y., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12356 · Cited by 5
Continuous glucose monitoring (Dexcom g6) in people with diabetes after kidney transplantation
Jakubowska, Z., & Małyszko, J. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2413007 · Cited by 6
Schmid, F., Mayer, C., Büttner-Herold, M. J., von Hörsten, S., Amann, K., & Daniel, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108691 · Cited by 4
Sanyal, D., Biswas, M., & Chaudhari, N. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.019 · Cited by 4
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
Bae, J., Kim, Y. J., Cho, Y., Lee, M., Lee, J.-Y., Lee, Y., Lee, B., Soo, B., Joo, D. J., Huh, K. H., et al. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.07.015 · Cited by 4
Treating posttransplantation diabetes mellitus
Pérez‐Sáez, M. J., Marín-Casino, M., & Pascual, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1039983 · Cited by 3
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
Nissaisorakarn, P., Pavlakis, M., & Aala, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.03.001 · Cited by 3
Hu, S., & Lan, G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1653147 · Cited by 3
Yamagishi, A., Nishida, H., Ito, H., Fukuhara, H., & Tsuchiya, N. (2022) · Renal Replacement Therapy · doi:10.1186/s41100-022-00421-8 · Cited by 3
POST-TRANSPLANT DIABETES MELLITUS (PTDM)
Goes, N. B. (2016) · Brazilian Journal of Medicine and Human Health · doi:10.17267/2317-3386bjmhh.v4i1.778 · Cited by 1
Cardiovascular Disease in Renal Transplantation
Lees, J. S., & Jardine, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00030-9 · Cited by 1
The causes of development and methods of correction of post-transplant diabetes mellitus
Lasareva, K. E., Николаевна, Р. О., & Zagorodnikova, N. V. (2017) · Transplantologiya The Russian Journal of Transplantation · doi:10.23873/2074-0506-2017-9-4-335-349 · Cited by 1
Diabetes in Kidney Transplant Recipients
Dhital, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_10 · Cited by 1
Tackling A Big Problem With Little Evidence: Improving Research Into Posttransplantation Diabetes
Sharif, A. (2016) · Endocrine Practice · doi:10.4158/ep161196.co
Galindo, D. E. B. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/12798
Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution
Oveyssi, J., & Huang, E. (2022) · Transplantation · doi:10.1097/tp.0000000000004374
Management of the Failing Pancreas Graft
Knight, R. J., Sadhu, A., & Gaber, A. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_69
Role of newer anti-diabetes drugs in prediabetes: A systematic review
Singh, A. K., & Singh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00037-2
Lee, K. Y., Song, G. Y., Seo, M. J., Kim, S. H., Kang, D. R., Park, K., Kim, J. T., Park, S. W., & Lee, J. Y. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.12.014
Evaluation and Management of Transplant-Associated Hyperglycemia
Bloom, R. D., & Moussallem, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_21
Fridell, J. A., Dunn, T. B., Oram, R. A., Sadhu, A., Spaggiari, M., Dib, Y. E., & Odorico, J. S. (2026) · Transplantation · doi:10.1097/tp.0000000000005757
Metadata
- Authors
- Werzowa, J., Hecking, M., Haidinger, M., Lechner, F., Döller, D., Pacini, G., Stemer, G., Pleiner, J., Frantal, S., & Säemann, M. D.
- Affiliations
- Medical University of Vienna (AT)
- National Research Council (IT)
- Vienna General Hospital (AT)
- Corresponding author
- Säemann, Marcus D.
- ORCID
- Venue
- Transplantation
- Published
- 2013-02-15
- Volume
- 95
- Issue
- 3
- Pages
- 456-462
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2314694833
- Cited by
- 87
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 10 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 16 · 2014: 10 · 2013: 5
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- vildagliptin, pioglitazone, impaired glucose tolerance, kidney transplantation, post-transplant diabetes mellitus, thiazolidinediones, oral glucose tolerance test, HbA1c, lifestyle counseling, diabetes treatment
- MeSH terms
- Pioglitazone, Vildagliptin, Adamantane, Aged, Blood Glucose, Diabetes Mellitus, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Nitriles, Pyrrolidines, Risk Factors, Kidney Transplantation, Treatment Outcome, Outcome Assessment, Health Care, Glucose Intolerance, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.